HIGH MOBILITY GROUP BOX-1 LEVELS IN SCHIZOPHRENIA: POTENTIAL BIOMARKER OF REMISSION PHASE

Basit Öğe Kaydı
dc.authoridYilmaz, Yavuz/0000-0002-7572-5474
dc.contributor.authorYilmaz, Nuryil
dc.contributor.authorYelboga, Zekeriya
dc.contributor.authorYilmaz, Yavuz
dc.contributor.authorDemirpence, Ozlem
dc.date.accessioned2024-10-26T18:04:13Z
dc.date.available2024-10-26T18:04:13Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases.Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases. Methods: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI). Results: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2.139 +/- 0.564 mu g/L vs. 2.326 +/- 0.471 mu g/L, p=0.335) and both were individually higher than the control group (1.791 +/- 0.444 mu g/L, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS. Conclusions: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespec- tive of phase, there were no differences between patients in acute exacerbation and remission phase in terms of biomarker and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia.
dc.identifier.doi10.5937/jomb0-28108
dc.identifier.endpage301
dc.identifier.issn1452-8258
dc.identifier.issn1452-8266
dc.identifier.issue3
dc.identifier.pmid34177374
dc.identifier.scopus2-s2.0-85115052460
dc.identifier.scopusqualityQ3
dc.identifier.startpage295
dc.identifier.urihttps://doi.org/10.5937/jomb0-28108
dc.identifier.urihttps://hdl.handle.net/20.500.12418/28817
dc.identifier.volume40
dc.identifier.wosWOS:000715092100009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSoc Medical Biochemists Serbia
dc.relation.ispartofJournal of Medical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectschizophrenia
dc.subjectHMGB-1
dc.subjectremission and acute exacerbation phase
dc.titleHIGH MOBILITY GROUP BOX-1 LEVELS IN SCHIZOPHRENIA: POTENTIAL BIOMARKER OF REMISSION PHASE
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu